PTEN Immunoexpression in Atypical Endometrial Hyperplasia and Endometrioid Endometrial Carcinoma: A Research Protocol
EK01-EK03
Correspondence
Dr. Garima Akhil Chandrakar,
Junior Resident, Department of Pathology, JNMC, Wardha-442005, Maharashtra, India.
E-mail: garimachandrakar27@gmail.com
Introduction: One of the major cancers affecting women is of Endometrial Carcinoma (EC). Therefore, its molecular characterisation remains important. Phosphatase and Tensin Homolog (PTEN) gene defects are one such molecular pathology commonly seen in lesion of atypical endometrial hyperplasia and EC. However, studies on PTEN immunoexpression in India are scarce.
Aim: To study immunoexpression of PTEN and its correlation with various clinicopathologic parameters in lesion of atypical endometrial hyperplasia and EC.
Materials and Methods: The study will be conducted in Department of Pathology for duration of two years from April 2022 to March 2024. It will be carried out as a cross-sectional study with prospective and retrospective design with sample size of 20 cases each in two groups- cases diagnosed on biopsy or surgical specimen of atypical endometrial hyperplasia and endometrioid endometrial carcinoma type -1, dividing them into sample size of 20 for each group. PTEN immunoexpression will be observed by immunohistochemical method on paraffin section of the tissue. The study would make the observation on the PTEN positivity by IHC in atypical endometrial hyperplasia and type-1 EC. The positive research of IHC will be compared for various other clinicopathologic parameters will be included in the study for both the endometrial lesion. The statistics of comparison will be drawn by using standard statistical test.